XKH001
Epithelium-derived cytokine IL-25 (also known as IL-17E) is one of central regulators for Type 2 immunity, providing important tissue-specific signals to both innate and adaptive cell populations throughout type 2 inflammation.
XKH001 is designed to bind to human IL-25 and block its interaction with IL-17RB/RA to prevent subsequent signaling activity, thereby inhibiting IL-25-induced type 2 inflammation
XKH001 is the only IL-25 targeted drug in the world that has entered clinical development stage, and it has obtained IND approval in both China and the United States. XKH001 is expected to provide a more precise and better treatment option for patients type 2 inflammatory diseases worldwide.
XKH001 patent applications have been submitted in several major countries, with patent granted in three countries, and the rest are in the substantive examination stage
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com